Protein kinase C as a target for cancer therapy.
Protein kinase C as a target for cancer therapy.
复制标题
蛋白激酶 C 作为癌症治疗的靶标。
DOI：
10.1089/oli.1.1997.7.235
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
Glazer,RI
中科院分区：
文献类型：
--
作者：
Glazer,RI
Glioblastoma multiforme (GM) is the most common form of brain cancer in adults, with a median survival time of less than 1 year (Mahaley et al., 1989). Unfortunately, this malignancy is not amenable to the traditional therapeutic modalities of surgery, radiation, and chemotherapy, and, there¬ fore, alternative approaches, such as antisense therapy, have been proposed (Dean et al, 1996; Hall et al., 1996). Prime molecular drug targets for antisense therapy are signal transduction molecules involved in the autocrine regulation ofGM proliferation through growth factor-dependent pathways (Guha et al, 1995; Harsh et al, 1990; Nister et al., 1988, 1991). One such target is protein kinase C (PKC), a multigene family consisting of 11 isoforms (Kikkawa et al., 1989; Parker et al., 1989). PKC is an essential component in the signaling path¬ ways for several growth factors that are involved in the prolifer¬ ation of GM (Couldwell et al., 1991, 1992; Vertosick, 1992). Although the role of PKC in cell function has become increas¬ ingly complex because of the identification of multiple PKC isoforms, all studies of GM cell lines (Ahmad et al., 1994; Mat-sumoto et al., 1995; Misra-Press et al., 1992; Shimosawa et al., 1990; Xiao et al., 1994), as well as primary malignant gliomas
